In this video, David M. Schuster, MD, FACR, discusses the background and findings of the study, “Detection rates of 18F-rhPSMA-7.3 PET in patients with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT),” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Schuster is a professor of urology and radiology and imaging sciences, a GRA distinguished cancer scientist, and the director of the division of nuclear medicine and molecular imaging at the Emory University School of Medicine in Atlanta, Georgia.
Enhancing the quality of bladder cancer care in the community setting
August 5th 2023Suzanne Merrill, MD, recaps the BCAN 2023 Think Tank session she co-chaired that covered prehabilitation programs, urinary diversion management, and other focal areas aimed at enhancing the quality of bladder cancer care in the community.
BCAN session to highlight epigenetics and response to immunotherapy in bladder cancer
August 3rd 2023"I'm really optimistic that the session we are conducting will provide some recommendations [and] some ideas that will help us think about utilizing epigenetic therapies in a very evidence-based way," says Ania Woloszynska, PhD.
2 Clarke Drive
Cranbury, NJ 08512